Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 23 entries
Sorted by: Best Match Show Resources per page
The natural killer cell response to HCV infection.

Immune network

Ahlenstiel G.
PMID: 24198741
Immune Netw. 2013 Oct;13(5):168-76. doi: 10.4110/in.2013.13.5.168. Epub 2013 Oct 26.

In the last few years major progress has been made in better understanding the role of natural killer (NK) cells in hepatitis C virus (HCV) infection. This includes multiple pathways by which HCV impairs or limits NK cells activation....

Cite
Ahlenstiel G. The natural killer cell response to HCV infection. Immune Netw. 2013;13(5):168-76doi: 10.4110/in.2013.13.5.168.
Ahlenstiel, G. (2013). The natural killer cell response to HCV infection. Immune network, 13(5), 168-76. https://doi.org/10.4110/in.2013.13.5.168
Ahlenstiel, Golo. "The natural killer cell response to HCV infection." Immune network vol. 13,5 (2013): 168-76. doi: https://doi.org/10.4110/in.2013.13.5.168
Ahlenstiel G. The natural killer cell response to HCV infection. Immune Netw. 2013 Oct;13(5):168-76. doi: 10.4110/in.2013.13.5.168. Epub 2013 Oct 26. PMID: 24198741; PMCID: PMC3817297.
Copy Download .nbib Format: NLM
Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort.

Genome medicine

Smith KR, Suppiah V, O'Connor K, Berg T, Weltman M, Abate ML, Spengler U, Bassendine M, Matthews G, Irving WL, Powell E, Riordan S, Ahlenstiel G, Stewart GJ, Bahlo M, George J, Booth DR.
PMID: 21884576
Genome Med. 2011 Aug 31;3(8):57. doi: 10.1186/gm273.

BACKGROUND: The hepatitis C virus (HCV) infects nearly 3% of the World's population, causing severe liver disease in many. Standard of care therapy is currently pegylated interferon alpha and ribavirin (PegIFN/R), which is effective in less than half of...

Cite
Smith KR, Suppiah V, O'Connor K, et al. Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Med. 2011;3(8):57doi: 10.1186/gm273.
Smith, K. R., Suppiah, V., O'Connor, K., Berg, T., Weltman, M., Abate, M. L., Spengler, U., Bassendine, M., Matthews, G., Irving, W. L., Powell, E., Riordan, S., Ahlenstiel, G., Stewart, G. J., Bahlo, M., George, J., Booth, D. R. (2011). Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome medicine, 3(8), 57. https://doi.org/10.1186/gm273
Smith, Katherine R, et al. "Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort." Genome medicine vol. 3,8 (2011): 57. doi: https://doi.org/10.1186/gm273
Smith KR, Suppiah V, O'Connor K, Berg T, Weltman M, Abate ML, Spengler U, Bassendine M, Matthews G, Irving WL, Powell E, Riordan S, Ahlenstiel G, Stewart GJ, Bahlo M, George J, Booth DR. Identification of improved IL28B SNPs and haplotypes for prediction of drug response in treatment of hepatitis C using massively parallel sequencing in a cross-sectional European cohort. Genome Med. 2011 Aug 31;3(8):57. doi: 10.1186/gm273. PMID: 21884576; PMCID: PMC3238183.
Copy Download .nbib Format: NLM
Pharmacogenomics of hepatitis C infections: personalizing therapy.

Genome medicine

Booth DR, Ahlenstiel G, George J.
PMID: 23268841
Genome Med. 2012 Dec 26;4(12):99. doi: 10.1186/gm400. eCollection 2012.

It is a widely held view that drug response genes have not proved as useful in clinical practice as anticipated at the start of the genomic era. An exception is in the treatment for chronic hepatitis C virus (HCV)...

Cite
Booth DR, Ahlenstiel G, George J. Pharmacogenomics of hepatitis C infections: personalizing therapy. Genome Med. 2012;4(12):99doi: 10.1186/gm400.
Booth, D. R., Ahlenstiel, G., & George, J. (2012). Pharmacogenomics of hepatitis C infections: personalizing therapy. Genome medicine, 4(12), 99. https://doi.org/10.1186/gm400
Booth, David R, et al. "Pharmacogenomics of hepatitis C infections: personalizing therapy." Genome medicine vol. 4,12 (2012): 99. doi: https://doi.org/10.1186/gm400
Booth DR, Ahlenstiel G, George J. Pharmacogenomics of hepatitis C infections: personalizing therapy. Genome Med. 2012 Dec 26;4(12):99. doi: 10.1186/gm400. eCollection 2012. PMID: 23268841; PMCID: PMC3580439.
Copy Download .nbib Format: NLM
Neutrophil Extracellular Trap Density Increases With Increasing Histopathological Severity of Crohn's Disease.

Inflammatory bowel diseases

Schroder AL, Chami B, Liu Y, Doyle CM, El Kazzi M, Ahlenstiel G, Ahmad G, Pathma-Nathan N, Collins G, Toh J, Harman A, Byrne S, Ctercteko G, Witting PK.
PMID: 34724042
Inflamm Bowel Dis. 2021 Nov 01; doi: 10.1093/ibd/izab239. Epub 2021 Nov 01.

BACKGROUND: Intestinal neutrophil recruitment is a characteristic feature of the earliest stages of inflammatory bowel disease (IBD). Neutrophil elastase (NE) and myeloperoxidase (MPO) mediate the formation of neutrophil extracellular traps (NETs); NETs produce the bactericidal oxidant hypochlorous acid (HOCl),...

Cite
Schroder AL, Chami B, Liu Y, et al. Neutrophil Extracellular Trap Density Increases With Increasing Histopathological Severity of Crohn's Disease. Inflamm Bowel Dis. 2021;doi: 10.1093/ibd/izab239.
Schroder, A. L., Chami, B., Liu, Y., Doyle, C. M., El Kazzi, M., Ahlenstiel, G., Ahmad, G., Pathma-Nathan, N., Collins, G., Toh, J., Harman, A., Byrne, S., Ctercteko, G., & Witting, P. K. (2021). Neutrophil Extracellular Trap Density Increases With Increasing Histopathological Severity of Crohn's Disease. Inflammatory bowel diseases, . https://doi.org/10.1093/ibd/izab239
Schroder, Angie L, et al. "Neutrophil Extracellular Trap Density Increases With Increasing Histopathological Severity of Crohn's Disease." Inflammatory bowel diseases vol. (2021). doi: https://doi.org/10.1093/ibd/izab239
Schroder AL, Chami B, Liu Y, Doyle CM, El Kazzi M, Ahlenstiel G, Ahmad G, Pathma-Nathan N, Collins G, Toh J, Harman A, Byrne S, Ctercteko G, Witting PK. Neutrophil Extracellular Trap Density Increases With Increasing Histopathological Severity of Crohn's Disease. Inflamm Bowel Dis. 2021 Nov 01; doi: 10.1093/ibd/izab239. Epub 2021 Nov 01. PMID: 34724042.
Copy Download .nbib Format: NLM
Optimal Isolation Protocols for Examining and Interrogating Mononuclear Phagocytes From Human Intestinal Tissue.

Frontiers in immunology

Doyle CM, Vine EE, Bertram KM, Baharlou H, Rhodes JW, Dervish S, Gosselink MP, Di Re A, Collins GP, Reza F, Toh JWT, Pathma-Nathan N, Ahlenstiel G, Ctercteko G, Cunningham AL, Harman AN, Byrne SN.
PMID: 34566985
Front Immunol. 2021 Sep 01;12:727952. doi: 10.3389/fimmu.2021.727952. eCollection 2021.

The human intestine contains numerous mononuclear phagocytes (MNP), including subsets of conventional dendritic cells (cDC), macrophages (Mf) and monocytes, each playing their own unique role within the intestinal immune system and homeostasis. The ability to isolate and interrogate MNPs...

Cite
Doyle CM, Vine EE, Bertram KM, et al. Optimal Isolation Protocols for Examining and Interrogating Mononuclear Phagocytes From Human Intestinal Tissue. Front Immunol. 2021;12:727952doi: 10.3389/fimmu.2021.727952.
Doyle, C. M., Vine, E. E., Bertram, K. M., Baharlou, H., Rhodes, J. W., Dervish, S., Gosselink, M. P., Di Re, A., Collins, G. P., Reza, F., Toh, J. W. T., Pathma-Nathan, N., Ahlenstiel, G., Ctercteko, G., Cunningham, A. L., Harman, A. N., & Byrne, S. N. (2021). Optimal Isolation Protocols for Examining and Interrogating Mononuclear Phagocytes From Human Intestinal Tissue. Frontiers in immunology, 12727952. https://doi.org/10.3389/fimmu.2021.727952
Doyle, Chloe M, et al. "Optimal Isolation Protocols for Examining and Interrogating Mononuclear Phagocytes From Human Intestinal Tissue." Frontiers in immunology vol. 12 (2021): 727952. doi: https://doi.org/10.3389/fimmu.2021.727952
Doyle CM, Vine EE, Bertram KM, Baharlou H, Rhodes JW, Dervish S, Gosselink MP, Di Re A, Collins GP, Reza F, Toh JWT, Pathma-Nathan N, Ahlenstiel G, Ctercteko G, Cunningham AL, Harman AN, Byrne SN. Optimal Isolation Protocols for Examining and Interrogating Mononuclear Phagocytes From Human Intestinal Tissue. Front Immunol. 2021 Sep 01;12:727952. doi: 10.3389/fimmu.2021.727952. eCollection 2021. PMID: 34566985; PMCID: PMC8462295.
Copy Download .nbib Format: NLM
Achieving HIV-1 Control through RNA-Directed Gene Regulation.

Genes

Klemm V, Mitchell J, Cortez-Jugo C, Cavalieri F, Symonds G, Caruso F, Kelleher AD, Ahlenstiel C.
PMID: 27941595
Genes (Basel). 2016 Dec 07;7(12). doi: 10.3390/genes7120119.

HIV-1 infection has been transformed by combined anti-retroviral therapy (ART), changing a universally fatal infection into a controllable infection. However, major obstacles for an HIV-1 cure exist. The HIV latent reservoir, which exists in resting CD4+ T cells, is...

Cite
Klemm V, Mitchell J, Cortez-Jugo C, et al. Achieving HIV-1 Control through RNA-Directed Gene Regulation. Genes (Basel). 2016;7(12)doi: 10.3390/genes7120119.
Klemm, V., Mitchell, J., Cortez-Jugo, C., Cavalieri, F., Symonds, G., Caruso, F., Kelleher, A. D., & Ahlenstiel, C. (2016). Achieving HIV-1 Control through RNA-Directed Gene Regulation. Genes, 7(12), . https://doi.org/10.3390/genes7120119
Klemm, Vera, et al. "Achieving HIV-1 Control through RNA-Directed Gene Regulation." Genes vol. 7,12 (2016). doi: https://doi.org/10.3390/genes7120119
Klemm V, Mitchell J, Cortez-Jugo C, Cavalieri F, Symonds G, Caruso F, Kelleher AD, Ahlenstiel C. Achieving HIV-1 Control through RNA-Directed Gene Regulation. Genes (Basel). 2016 Dec 07;7(12). doi: 10.3390/genes7120119. PMID: 27941595; PMCID: PMC5192495.
Copy Download .nbib Format: NLM
Controlling HIV-1: Non-Coding RNA Gene Therapy Approaches to a Functional Cure.

Frontiers in immunology

Ahlenstiel CL, Suzuki K, Marks K, Symonds GP, Kelleher AD.
PMID: 26441979
Front Immunol. 2015 Sep 16;6:474. doi: 10.3389/fimmu.2015.00474. eCollection 2015.

The current treatment strategy for HIV-1 involves prolonged and intensive combined antiretroviral therapy (cART), which successfully suppresses plasma viremia. It has transformed HIV-1 infection into a chronic disease. However, despite the success of cART, a latent form of HIV-1...

Cite
Ahlenstiel CL, Suzuki K, Marks K, et al. Controlling HIV-1: Non-Coding RNA Gene Therapy Approaches to a Functional Cure. Front Immunol. 2015;6:474doi: 10.3389/fimmu.2015.00474.
Ahlenstiel, C. L., Suzuki, K., Marks, K., Symonds, G. P., & Kelleher, A. D. (2015). Controlling HIV-1: Non-Coding RNA Gene Therapy Approaches to a Functional Cure. Frontiers in immunology, 6474. https://doi.org/10.3389/fimmu.2015.00474
Ahlenstiel, Chantelle L, et al. "Controlling HIV-1: Non-Coding RNA Gene Therapy Approaches to a Functional Cure." Frontiers in immunology vol. 6 (2015): 474. doi: https://doi.org/10.3389/fimmu.2015.00474
Ahlenstiel CL, Suzuki K, Marks K, Symonds GP, Kelleher AD. Controlling HIV-1: Non-Coding RNA Gene Therapy Approaches to a Functional Cure. Front Immunol. 2015 Sep 16;6:474. doi: 10.3389/fimmu.2015.00474. eCollection 2015. PMID: 26441979; PMCID: PMC4584958.
Copy Download .nbib Format: NLM
Once-daily tacrolimus extended-release formulation: 1 year after conversion in stable pediatric kidney transplant recipients.

International journal of nephrology

Pape L, Heidotting N, Ahlenstiel T.
PMID: 21647310
Int J Nephrol. 2011;2011:126251. doi: 10.4061/2011/126251. Epub 2011 May 22.

It is speculated that a once-daily dosage of immunosuppression can increase adherence and thereby graft survival. Until now, there have been no studies on once-daily use of Tacrolimus extended-release formulation (TAC-ER) in children following pediatric kidney transplantation. In 11...

Cite
Pape L, Heidotting N, Ahlenstiel T. Once-daily tacrolimus extended-release formulation: 1 year after conversion in stable pediatric kidney transplant recipients. Int J Nephrol. 2011;2011:126251doi: 10.4061/2011/126251.
Pape, L., Heidotting, N., & Ahlenstiel, T. (2011). Once-daily tacrolimus extended-release formulation: 1 year after conversion in stable pediatric kidney transplant recipients. International journal of nephrology, 2011126251. https://doi.org/10.4061/2011/126251
Pape, Lars, et al. "Once-daily tacrolimus extended-release formulation: 1 year after conversion in stable pediatric kidney transplant recipients." International journal of nephrology vol. 2011 (2011): 126251. doi: https://doi.org/10.4061/2011/126251
Pape L, Heidotting N, Ahlenstiel T. Once-daily tacrolimus extended-release formulation: 1 year after conversion in stable pediatric kidney transplant recipients. Int J Nephrol. 2011;2011:126251. doi: 10.4061/2011/126251. Epub 2011 May 22. PMID: 21647310; PMCID: PMC3106355.
Copy Download .nbib Format: NLM
Novel RNA Duplex Locks HIV-1 in a Latent State via Chromatin-mediated Transcriptional Silencing.

Molecular therapy. Nucleic acids

Ahlenstiel C, Mendez C, Lim ST, Marks K, Turville S, Cooper DA, Kelleher AD, Suzuki K.
PMID: 26506039
Mol Ther Nucleic Acids. 2015 Oct 27;4:e261. doi: 10.1038/mtna.2015.31.

Transcriptional gene silencing (TGS) of mammalian genes can be induced by short interfering RNA (siRNA) targeting promoter regions. We previously reported potent TGS of HIV-1 by siRNA (PromA), which targets tandem NF-κB motifs within the viral 5'LTR. In this...

Cite
Ahlenstiel C, Mendez C, Lim ST, et al. Novel RNA Duplex Locks HIV-1 in a Latent State via Chromatin-mediated Transcriptional Silencing. Mol Ther Nucleic Acids. 2015;4:e261doi: 10.1038/mtna.2015.31.
Ahlenstiel, C., Mendez, C., Lim, S. T., Marks, K., Turville, S., Cooper, D. A., Kelleher, A. D., & Suzuki, K. (2015). Novel RNA Duplex Locks HIV-1 in a Latent State via Chromatin-mediated Transcriptional Silencing. Molecular therapy. Nucleic acids, 4e261. https://doi.org/10.1038/mtna.2015.31
Ahlenstiel, Chantelle, et al. "Novel RNA Duplex Locks HIV-1 in a Latent State via Chromatin-mediated Transcriptional Silencing." Molecular therapy. Nucleic acids vol. 4 (2015): e261. doi: https://doi.org/10.1038/mtna.2015.31
Ahlenstiel C, Mendez C, Lim ST, Marks K, Turville S, Cooper DA, Kelleher AD, Suzuki K. Novel RNA Duplex Locks HIV-1 in a Latent State via Chromatin-mediated Transcriptional Silencing. Mol Ther Nucleic Acids. 2015 Oct 27;4:e261. doi: 10.1038/mtna.2015.31. PMID: 26506039; PMCID: PMC4881759.
Copy Download .nbib Format: NLM
Hepatitis C Virus (HCV) Eradication With Interferon-Free Direct-Acting Antiviral-Based Therapy Results in KLRG1+ HCV-Specific Memory Natural Killer Cells.

The Journal of infectious diseases

Wijaya RS, Read SA, Selvamani SP, Schibeci S, Azardaryany MK, Ong A, van der Poorten D, Lin R, Douglas MW, George J, Ahlenstiel G.
PMID: 32777077
J Infect Dis. 2021 Apr 08;223(7):1183-1195. doi: 10.1093/infdis/jiaa492.

Direct acting antiviral therapies rapidly clear chronic hepatitis C virus (HCV) infection and restore natural killer (NK) cell function. We investigated NK-cell memory formation following HCV clearance by examining NK-cell phenotype and responses from control and chronic HCV patients...

Cite
Wijaya RS, Read SA, Selvamani SP, et al. Hepatitis C Virus (HCV) Eradication With Interferon-Free Direct-Acting Antiviral-Based Therapy Results in KLRG1+ HCV-Specific Memory Natural Killer Cells. J Infect Dis. 2021;223(7):1183-1195doi: 10.1093/infdis/jiaa492.
Wijaya, R. S., Read, S. A., Selvamani, S. P., Schibeci, S., Azardaryany, M. K., Ong, A., van der Poorten, D., Lin, R., Douglas, M. W., George, J., & Ahlenstiel, G. (2021). Hepatitis C Virus (HCV) Eradication With Interferon-Free Direct-Acting Antiviral-Based Therapy Results in KLRG1+ HCV-Specific Memory Natural Killer Cells. The Journal of infectious diseases, 223(7), 1183-1195. https://doi.org/10.1093/infdis/jiaa492
Wijaya, Ratna S, et al. "Hepatitis C Virus (HCV) Eradication With Interferon-Free Direct-Acting Antiviral-Based Therapy Results in KLRG1+ HCV-Specific Memory Natural Killer Cells." The Journal of infectious diseases vol. 223,7 (2021): 1183-1195. doi: https://doi.org/10.1093/infdis/jiaa492
Wijaya RS, Read SA, Selvamani SP, Schibeci S, Azardaryany MK, Ong A, van der Poorten D, Lin R, Douglas MW, George J, Ahlenstiel G. Hepatitis C Virus (HCV) Eradication With Interferon-Free Direct-Acting Antiviral-Based Therapy Results in KLRG1+ HCV-Specific Memory Natural Killer Cells. J Infect Dis. 2021 Apr 08;223(7):1183-1195. doi: 10.1093/infdis/jiaa492. PMID: 32777077.
Copy Download .nbib Format: NLM
Efficacy of Telephone Health Coaching Integration with Standard Multidisciplinary Care for Adults with Obesity Attending a Weight Management Service: A Pilot Study.

Nutrients

Driscoll S, Meyerowitz-Katz G, Ahlenstiel G, Reynolds T, Reid K, Bishay RH.
PMID: 34836331
Nutrients. 2021 Nov 15;13(11). doi: 10.3390/nu13114078.

Australia has one of the highest prevalences of obesity in the developed world with recognised gaps in patient access to obesity services. This non-randomised before and after study investigated the health benefits and patient acceptability of integrating the Get...

Cite
Driscoll S, Meyerowitz-Katz G, Ahlenstiel G, et al. Efficacy of Telephone Health Coaching Integration with Standard Multidisciplinary Care for Adults with Obesity Attending a Weight Management Service: A Pilot Study. Nutrients. 2021;13(11)doi: 10.3390/nu13114078.
Driscoll, S., Meyerowitz-Katz, G., Ahlenstiel, G., Reynolds, T., Reid, K., & Bishay, R. H. (2021). Efficacy of Telephone Health Coaching Integration with Standard Multidisciplinary Care for Adults with Obesity Attending a Weight Management Service: A Pilot Study. Nutrients, 13(11), . https://doi.org/10.3390/nu13114078
Driscoll, Sarah, et al. "Efficacy of Telephone Health Coaching Integration with Standard Multidisciplinary Care for Adults with Obesity Attending a Weight Management Service: A Pilot Study." Nutrients vol. 13,11 (2021). doi: https://doi.org/10.3390/nu13114078
Driscoll S, Meyerowitz-Katz G, Ahlenstiel G, Reynolds T, Reid K, Bishay RH. Efficacy of Telephone Health Coaching Integration with Standard Multidisciplinary Care for Adults with Obesity Attending a Weight Management Service: A Pilot Study. Nutrients. 2021 Nov 15;13(11). doi: 10.3390/nu13114078. PMID: 34836331; PMCID: PMC8625904.
Copy Download .nbib Format: NLM
Promoter Targeting shRNA Suppresses HIV-1 Infection In vivo Through Transcriptional Gene Silencing.

Molecular therapy. Nucleic acids

Suzuki K, Hattori S, Marks K, Ahlenstiel C, Maeda Y, Ishida T, Millington M, Boyd M, Symonds G, Cooper DA, Okada S, Kelleher AD.
PMID: 24301868
Mol Ther Nucleic Acids. 2013 Dec 03;2:e137. doi: 10.1038/mtna.2013.64.

Despite prolonged and intensive application, combined antiretroviral therapy cannot eradicate human immunodeficiency virus (HIV)-1 because it is harbored as a latent infection, surviving for long periods of time. Alternative approaches are required to overcome the limitations of current therapy....

Cite
Suzuki K, Hattori S, Marks K, et al. Promoter Targeting shRNA Suppresses HIV-1 Infection In vivo Through Transcriptional Gene Silencing. Mol Ther Nucleic Acids. 2013;2:e137doi: 10.1038/mtna.2013.64.
Suzuki, K., Hattori, S., Marks, K., Ahlenstiel, C., Maeda, Y., Ishida, T., Millington, M., Boyd, M., Symonds, G., Cooper, D. A., Okada, S., & Kelleher, A. D. (2013). Promoter Targeting shRNA Suppresses HIV-1 Infection In vivo Through Transcriptional Gene Silencing. Molecular therapy. Nucleic acids, 2e137. https://doi.org/10.1038/mtna.2013.64
Suzuki, Kazuo, et al. "Promoter Targeting shRNA Suppresses HIV-1 Infection In vivo Through Transcriptional Gene Silencing." Molecular therapy. Nucleic acids vol. 2 (2013): e137. doi: https://doi.org/10.1038/mtna.2013.64
Suzuki K, Hattori S, Marks K, Ahlenstiel C, Maeda Y, Ishida T, Millington M, Boyd M, Symonds G, Cooper DA, Okada S, Kelleher AD. Promoter Targeting shRNA Suppresses HIV-1 Infection In vivo Through Transcriptional Gene Silencing. Mol Ther Nucleic Acids. 2013 Dec 03;2:e137. doi: 10.1038/mtna.2013.64. PMID: 24301868; PMCID: PMC3894581.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 23 entries